Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma.
about
Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trialEpstein-Barr virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-κB pathways: impairment in T cell functions.Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenaseCancer prevention and therapy through the modulation of the tumor microenvironment.Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma.Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatinThe status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy.Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.Tumor-Associated Fibroblasts and Microvessels Contribute to the Expression of Immunosuppressive Factor Indoleamine 2, 3-Dioxygenase in Human Esophageal Cancers.Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer.
P2860
Q28820954-F4D6DFE9-449F-4FEB-B8C4-D507089A40BFQ33743826-95E72FA1-EB9D-4314-B812-921AEBF8DF4FQ35109049-C9CECFD9-F5B5-4E74-AA7C-58EFE3939B5AQ37058267-072A105F-416B-4A4A-AC18-D1AC9AF03D11Q38571347-791F2E6D-A9C1-4FC3-81FA-DAAAA40F202FQ39514618-172BF0CA-44A0-4523-B632-3E9535DC3237Q40721415-5CBB60A7-4EE5-49B5-9204-1A52A957A396Q41149149-737D004E-1EB4-43A6-902C-57D4DE92B5F5Q47165141-2662BA99-3524-419C-BA26-256DC184EAA0Q48306002-E04CE43E-B8C6-473A-A56F-7AC2B6E98A87Q49071066-35EE4AC9-72A8-43D0-9326-6B6D541DB2E3Q50103704-6048758F-8FA9-4784-9CC6-8B213E843912Q52873461-1CDF9F29-5B54-45B8-B8AB-436246D7D173Q55002224-27FC0DCA-6F40-4208-AAB2-A312533E91EF
P2860
Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Involvement of indoleamine 2,3 ...... ageal squamous cell carcinoma.
@ast
Involvement of indoleamine 2,3 ...... ageal squamous cell carcinoma.
@en
type
label
Involvement of indoleamine 2,3 ...... ageal squamous cell carcinoma.
@ast
Involvement of indoleamine 2,3 ...... ageal squamous cell carcinoma.
@en
prefLabel
Involvement of indoleamine 2,3 ...... ageal squamous cell carcinoma.
@ast
Involvement of indoleamine 2,3 ...... ageal squamous cell carcinoma.
@en
P2093
P2860
P356
P1476
Involvement of indoleamine 2,3 ...... ageal squamous cell carcinoma.
@en
P2093
Jun-Ye Wang
Miao-Huan Kuang
Shu-Qin Dai
Wan-Li Liu
Yue-Hao Lin
P2860
P304
P356
10.1155/2011/384726
P577
2011-10-13T00:00:00Z